These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 26962792

  • 1. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
    Xiong J, Altaf K, Ke N, Wang Y, Tang J, Tan C, Li A, Zhang H, He D, Liu X.
    Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
    [Abstract] [Full Text] [Related]

  • 2. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
    Si S, Liao Q, Zhao YP, Hu Y, Zhang Q, You LL.
    Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
    [Abstract] [Full Text] [Related]

  • 3. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.
    Cancer Biol Ther; 2014 Jun 01; 15(6):688-98. PubMed ID: 24618665
    [Abstract] [Full Text] [Related]

  • 4. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL.
    Gastroenterology; 2012 Sep 01; 143(3):664-674.e6. PubMed ID: 22705007
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M, Pach R, Kulig P, Legutko J, Kulig J.
    Pancreas; 2017 Sep 01; 46(5):684-689. PubMed ID: 28196013
    [Abstract] [Full Text] [Related]

  • 6. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
    Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem JL.
    Cancer; 2010 Nov 15; 116(22):5200-6. PubMed ID: 20669326
    [Abstract] [Full Text] [Related]

  • 7. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S, Ueda T, Komuro A, Amano H, Honda M, Kawazu M, Okada H.
    Mol Cancer Res; 2023 May 01; 21(5):444-457. PubMed ID: 36757299
    [Abstract] [Full Text] [Related]

  • 8. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
    Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D.
    Clin Cancer Res; 2010 Jan 01; 16(1):320-9. PubMed ID: 20028759
    [Abstract] [Full Text] [Related]

  • 9. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 01; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 10. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S, Ueda T, Komuro A, Honda M, Sugisawa R, Okada H.
    Cell Death Dis; 2024 Feb 12; 15(2):131. PubMed ID: 38346958
    [Abstract] [Full Text] [Related]

  • 11. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR.
    Cancer Res; 2009 Jun 01; 69(11):4567-72. PubMed ID: 19487279
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA.
    Clin Cancer Res; 2006 Apr 15; 12(8):2492-7. PubMed ID: 16638857
    [Abstract] [Full Text] [Related]

  • 13. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A, Puleo F, Bachet JB, Ouazzani S, Calomme A, Demetter P, Verset G, Van Laethem JL, Maréchal R.
    Br J Cancer; 2016 Nov 08; 115(10):1245-1252. PubMed ID: 27755532
    [Abstract] [Full Text] [Related]

  • 14. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y, Ji B, Jiang CX, Chen ZM, Yao NH, Mukaida N, Huang H.
    Pathol Res Pract; 2019 Dec 08; 215(12):152650. PubMed ID: 31585811
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
    Ohmine K, Kawaguchi K, Ohtsuki S, Motoi F, Ohtsuka H, Kamiie J, Abe T, Unno M, Terasaki T.
    Mol Pharm; 2015 Sep 08; 12(9):3282-91. PubMed ID: 26280109
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U.
    Cancer Res; 2010 Jun 01; 70(11):4528-38. PubMed ID: 20460539
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
    Bird NT, Elmasry M, Jones R, Psarelli E, Dodd J, Malik H, Greenhalf W, Kitteringham N, Ghaneh P, Neoptolemos JP, Palmer D.
    Br J Surg; 2017 Mar 01; 104(4):328-336. PubMed ID: 28199010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.